3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase 1/2
3
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
89
Leukemia
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma
26
Leukemia, Erythroblastic, Acute
19
Leukemia, Myelomonocytic, Acute
18
Leukemia, Monocytic, Acute
18
Leukemia, Megakaryoblastic, Acute
18
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Myelodysplastic Syndromes
10
Lymphoma, Non-Hodgkin
10
Anemia, Refractory, with Excess of Blasts
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Eosinophilic, Acute
6
Recurrence
5
Myeloproliferative Disorders
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Promyelocytic, Acute
5
Leukemia, Biphenotypic, Acute
5
Leukemia, Basophilic, Acute
5
Hodgkin Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Multiple Myeloma
4
Interventions
Imatinib Mesylate
5
nilotinib
3
ponatinib
2
thymoglobulin
1
enasidenib
1
bosutinib
1
Transplantation
1
Standard of Care
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Hematopoietic Stem Cell Transplantation
1
Cytarabine
1
Cyclosporine
1
BID protein, human
1
Azacitidine
1
Antilymphocyte Serum
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid
×
Cytarabine
×
Clear all
NCT02577406
2025-05-18
IDHENTIFY
Celgene
Phase 3
Completed
319 enrolled
29 charts